2-DG), an antiviral drug used for treating Covid-19 patients, under the brand name ‘DGJAJ’ in collaboration with Defence Research and Development Organisation (DRDO).
The API manufacturer had received a licence from DRDO to manufacture the anti-Covid medication on July 7. The production of DGJAJ began from today onwards, the company said in a regulatory filing on Sunday. “Health experts are anticipating a third wave of Covid-19, which may be even more severe as the virus has undergone several mutations over the time.
We hope the availability of an effective treatment such as 2-Deoxy-D-Glucose (2-DG) will offer patients with much needed and timely therapy option," said Anil Jain, Joint Managing Director of Bajaj Healthcare.